NewAmsterdam Pharma heads into the autumn with a curious split: short interest has risen sharply over the past month while the options market has turned markedly less bearish — two signals pointing in opposite directions on a stock already down 8% in a month.
The short side tells a clear story of accumulating pressure. Short interest has climbed 38% in a month, reaching 11.2% of the free float — a level that qualifies as meaningfully elevated for a clinical-stage biotech. The sharpest build came around August 24-25, when shorts jumped by roughly 2.6 million shares in a single session, taking the position from around 10 million to nearly 12.7 million shares. Despite that, borrowing costs remain remarkably subdued at just 0.51% annually, and availability is extremely loose at 855% — meaning there are roughly eight-and-a-half shares available to borrow for every one already borrowed. Short sellers can add to positions freely; the lack of any lending squeeze suggests this is conviction-driven shorting rather than a crowded trade approaching a technical friction point.
Options tell a contrasting story. The put/call ratio has dropped sharply from extreme defensive levels seen earlier in the summer — readings above 6.5 in early August — to 3.27 now, which sits nearly 1.4 standard deviations its 20-day mean of 4.84. That is the lowest defensive positioning in weeks. Put-heavy positioning has been the dominant stance for months, with the 52-week high PCR touching 9.8. The recent pullback in that ratio — as calls gain relative weight — suggests at least some participants are trimming downside hedges or positioning for a recovery. Short interest builds while options hedges ease: the tension is real.
The Street remains firmly bullish on the thesis, even as near-term momentum fades. Multiple analysts carry Buy or Outperform ratings, with targets clustered in the $45-$52 range against a current price of $25.40 — implying roughly 70-100% upside on consensus. RBC Capital, one of the closer followers of the name, trimmed its target modestly to $50 from $51 in early August while holding its Outperform rating, a signal that conviction is intact but expectations are being calibrated. Goldman Sachs remains the outlier with a Neutral and a $37 target. The bull case centres on obicetrapib's potential in the cardiometabolic market, with estimated global sales of $3.1 billion cited by supporters. The bear case is well-known: no revenue, negative earnings (trailing PE around -15.8x), heavy cash burn, and a 2027 patent cliff that narrows the commercial window. The ORTEX short score has been drifting higher, reaching 65.4 this week — a moderate reading that reflects elevated short interest without signalling an imminent squeeze.
Institutional ownership adds another layer of complexity. The register carries two active 13D filers — ForGrowth NAP B.V. at 8.3% and Frazier Life Sciences Public Fund at 7.7% — both of whom have filed activist-intent schedules. That is a notable feature for a company of this size, signalling that the largest shareholders are not passive. FMR (Fidelity) and Capital Research have both added meaningfully in recent months, each building positions now above 8-10% of shares. On the other side, Bain Capital Life Sciences trimmed by 3.5 million shares in the last reported period, and the overall insider picture over the past 90 days shows net open-market sales of roughly $7.8 million in value — all executed under pre-arranged 10b5-1 plans, which limits the signal value but confirms insiders have been taking cash off the table.
Earnings history reinforces caution around the next print. The last two quarterly reports produced a -2.3% day-one reaction and a -5.2% day-one drop respectively, with the five-day moves compounding further losses to -6.1% and -8.1%. The upcoming November 5 event is the next date to ring-fence. Between now and then, the key variable is whether short sellers continue building into loose borrow conditions while the options market's reduced defensive tone holds — or whether one side of that divergence snaps back into alignment.
See the live data behind this article on ORTEX.
Open NAMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
